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Nitric oxide in chronic renal failure. Endothelium-derived ni-
tric oxide (NO) is critically involved in the regulation of a wide
variety of vascular functions. It had been hypothesized that a
deficiency of vascular NO might be involved in the accelerated
atherosclerosis and dramatic cardiovascular mortality observed
in patients with chronic renal failure. At present it is difficult
to measure authentic NO in vivo. An alternative is to study
NO by its effect on vascular tone by using the forearm blood
flow technique. In this way, studies demonstrated an unimpaired
availability of NO under baseline conditions but a profound re-
duction of agonist-induced endothelium-dependent vasodilata-
tion in uremic patients. Further investigation showed that the
latter phenomenon is mainly attributable to a reduced avail-
ability of vascular NO upon agonist stimulation, while the NO-
independent mechanism(s) appear(s) to be intact in this set-
ting. Explanations for this finding include an uncoupling of NO
synthase induced by cofactor deficiency, and/or a reduced NO
availability caused by high levels of oxidative stress. Recent data
suggest only a minor role for cytochrome-P450 2C9-dependent
pathways in this context. Future studies have to show which
mechanisms are most relevant, and whether they are sensitive
to therapeutic intervention.
Since the discovery of the endothelium-derived relax-
ing factor and its subsequent identification as nitric oxide,
there was hardly one molecule which has gained so much
interest in medical science. While nitric oxide is involved
in a wide variety of physiologic functions, its role as an
endothelium-derived mediator has been most extensively
studied in cardiovascular medicine. In this context nitric
oxide has turned out to be a central mediator involved
in various vascular functions. Because of its vasodilatory,
antiproliferative, and antithrombogenic properties, nitric
oxide has been predominantly regarded as an antiathero-
genic compound. It is now clear, however, that under con-
ditions of increased oxidative stress nitric oxide may be
involved in vascular damage and atherosclerosis, too [1].
Alterations of the vascular nitric oxide system have been
observed very early in the development of atherosclero-
sis. Such early stage of atherosclerosis, termed endothelial
dysfunction, is associated with a reduced bioavailability
of nitric oxide and can be assessed by an impairment of
endothelium-dependent vasodilatation [2].
Uremia is a state of increased cardiovascular morbid-
ity and mortality and therefore believed to be associated
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with accelerated atherosclerosis [3, 4]. It is therefore not
surprising that considerable scientific interest focused on
alterations of the vascular nitric oxide system in uremic
subjects to find explanations and therapeutic options for
their excessive cardiovascular mortality. The discovery of
endogenous nitric oxide synthase (NOS) inhibitors gave
rise to the hypothesis that uremia might be a state of nitric
oxide deficiency [5].
At present it is very difficult, if not impossible, to mea-
sure authentic nitric oxide in vivo. Therefore various at-
tempts have been made to estimate total body nitric oxide
production in animal models as well as in patients with
chronic renal failure by a variety of surrogate parame-
ters. Unfortunately, these studies have revealed contro-
versial results. For example, by determination of arginine-
to-citrulline conversion, Wever et al [6] found a reduced
total nitric oxide production in patients with advanced
renal insufficiency. In contrast, by using a comparable
experimental setup, Lau et al [7] reported on enhanced
nitric oxide synthesis in patients on hemodialysis. Mea-
surements of plasma levels of stable nitric oxide metabo-
lites or of concentrations of exhaled nitric oxide have
resulted in discrepant findings, too [8, 9]. In fact the lit-
erature contains lines of evidence supporting enhanced
as well as reduced nitric oxide synthesis in uremia. These
controversies may be related to the fact that nitric oxide
can be metabolized in different ways. Thus measurements
of one stable metabolite do not necessarily reflect total ni-
tric oxide synthesis. In addition, determinations of nitric
oxide synthesis do not provide reliable information about
its bioavailability. To aggravate this situation it is unclear
to which extent total body nitric oxide measurements are
representative for vascular nitric oxide production [10].
A promising way to circumvent these difficulties is to
study the effects of NOS stimulation and subsequent ni-
tric oxide release directly by measurement of the result-
ing changes in vascular tone. One such approach deter-
mines the dilatation of the brachial artery in response to
postischemic increase in blood flow. In this way Kari et al
[11] were the first to demonstrate an impairment of flow-
mediated dilatation in children with renal insufficiency
indicating that uremic intoxication per se is associated
with endothelial dysfunction and impaired bioavailability
of nitric oxide upon shear stress–induced stimulation of
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the endothelium. Unfortunately, it is not possible to study
the contribution of nitric oxide to baseline vascular tone
by this method. Such more complex vascular testing can
be accomplished by using the forearm blood flow tech-
nique. Here locally active doses of vasoactive substances
are infused into the brachial artery of one arm and the
resulting changes in forearm blood flow are measured by
venous occlusion plethysmography. In this way we could
repeatedly show that vasoconstriction of forearm resis-
tance vessels in response to the NOS inhibitor L-NMMA
is not reduced in otherwise healthy uremic patients [12,
13]. Together with the previous finding that nitric oxide
generation in uremic platelets is even enhanced [14, 15]
our results do not support the hypothesis of a general im-
pairment of nitric oxide synthesis in renal insufficiency.
Further experiments in comparable groups of pa-
tients, however, demonstrated a profound impairment
of vasodilatation upon endothelial stimulation with mus-
carinic agonists such as carbachol or acetylcholine [12,
16]. These findings confirmed the results obtained by Kari
et al [11] and provided further evidence that uremia is a
state of endothelial dysfunction. However, these results
per se still cannot be regarded as evidence for an impair-
ment of stimulated nitric oxide release in this setting as cy-
clooxygenase is stimulated by agonists, too, which in turn
generates vasodilatory prostacyclin I2 (PGI2). Further-
more, a significant portion of agonist-induced endothe-
lium dependent vasodilation is resistant to concomitant
blockade of NOS and cyclooxygenases and has been at-
tributed to the release of endothelium-dependent hyper-
polarizing factors (EDHF) (reviewed in [17]). It is con-
ceivable that uremia interferes with EDHF-associated
signaling pathways, too. Such results have been obtained
in isolated vessels of 5/6 nephrectomized rats [18]. We
have therefore performed further experiments in uremic
subjects by employing the nitric oxide clamp technique.
The latter approach allowed us to study the contributions
of nitric oxide and nitric oxide/PGI2-independent mech-
anisms to agonist-induced vasodilatation separately. By
using an extended dose range of acetylcholine (1 to 300
nmol/min) we could demonstrate a preserved nitric oxide
stimulation in response to lower doses of this muscarinic
agonist. Infusions of higher doses of acetylcholine, how-
ever, were associated with a brisk and substantial decline
of nitric oxide–mediated vasodilatation in uremic sub-
jects while those relaxations elicited by nitric oxide/PGI2-
independent mechanisms were at control level or even in-
creased. This study provides first evidence in humans that
uremic endothelial dysfunction as measured by agonist-
induced, endothelium-dependent vasodilatation is at-
tributable to an impairment of vascular nitric oxide. Fur-
thermore, the particular pattern of vascular responses
observed may help to understand the underlying mecha-
nisms of nitric oxide impairment in uremia. Generally, the
latter may result from decreased nitric oxide generation
or increased nitric oxide breakdown by oxidative com-
pounds. In the literature, decreased nitric oxide genera-
tion is usually explained by the presence of endogenous
competitive NOS inhibitors [asymmetrical dimethyl-
arginine (ADMA)] [19]. In fact, competitive inhibition
of an enzyme results in a rightward shift of the dose-
response curve of an agonist. Our results, however, are
not compatible with that particular pattern of response
as vascular release of nitric oxide at baseline and dur-
ing low-dose acetylcholine was unaffected in uremia. It is
therefore unlikely that constant levels of such compounds
are mainly responsible for the nitric oxide impairment
observed. This view is further substantiated by the fact
that neither acute [20] nor chronic [21] supplementation
with L-arginine was able to improve endothelial function
in patients with renal failure. There is one report in the
literature showing an increase of ADMA generation in
endothelial cells in response to shear stress [22]. How-
ever, whether the magnitude of the observed changes can
sufficiently explain such profound impairment of stimu-
lated nitric oxide as seen in our study requires further
investigation.
A more likely explanation for the characteristics of ni-
tric oxide stimulation observed in our studies could be
uncoupling of endothelial NOS (eNOS), which in turn
may be caused by substrate and/or cofactor deficiency oc-
curring at a certain degree of agonist stimulation. In this
context, uremia-associated changes in L-arginine trans-
port (responsible for the delivery of substrate to NOS
[23]) as well as alterations in pteridine metabolism (pro-
viding tetrahydrobiopterin as a critical cofactor of nitric
oxide synthesis [24], have been observed. Further studies
are needed to clarify this issue.
Uncoupling of eNOS does not only result in reduced ni-
tric oxide production but is also associated with increased
oxidative stress by generation of superoxide anions which
in turn cause further nitric oxide degradation by forming
peroxynitrite. The presence of high levels of oxidative
stress in uremia has been demonstrated in various stud-
ies [25–27].
Apart from eNOS itself, there may be other factors po-
tentially involved in the generation of uremic oxidative
stress, including NAD(P)H oxidase [28], hyperhomocys-
teinemia [29], and myeloperoxidase [30]. Recently, a cy-
tochrome P450 (CYP 2C)-dependent epoxygenase has
been shown to generate reactive oxygen species which
interfere with the bioavailability of nitric oxide and conse-
quently interfere with nitric oxide–mediated vasodilata-
tion and the expression of redox-sensitive genes [31]. The
latter mechanism appears to dominate in situations of en-
dothelial dysfunction since a considerable improvement
in the acetylcholine-induced nitric oxide–dependent va-
sodilatation of the forearm vasculature was recorded
in patients with coronary heart disease when CYP 2C9
was inhibited [32]. We have recently tested whether this
pathway contributes to uremic endothelial dysfunction,
too. Inhibition of CYP 2C9 by sulfaphenazole was not
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able to improve acetylcholine-induced, endothelium-
dependent vasodilatation in hemodialysis patients with-
out clinical signs of atherosclerotic disease [33]. This find-
ing may indicate that vascular expression of CYP 2C9 and
subsequent inactivation of nitric oxide by reactive oxygen
species is not involved in early endothelial dysfunction of
uremic subjects.
CONCLUSION
We have so far demonstrated that in a local vascular
bed of uremic subjects the contribution of nitric oxide to
baseline vascular tone is at control level. We provided first
evidence in humans that uremic endothelial dysfunction
as measured by agonist-induced endothelium-dependent
vasodilatation is attributable to an impairment of nitric
oxide. In this context uncoupling of eNOS and/or nitric
oxide consumption by uremic oxidative stress are possi-
ble explanations for this finding while the role of ADMA
remains controversial. Furthermore, CYP 2C9-derived
reactive oxygen species are unlikely to be involved in
early endothelial dysfunction of uremic subjects.
Taken together there are various mechanisms by which
uremic intoxication might interfere with the bioavail-
ability of vascular nitric oxide. Future studies have to
show which of these mechanisms are most relevant and
whether they are sensitive to therapeutic intervention.
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